Explore 3 Stock Ideas & Industry Insights Download Free Report

800-234-336
Shopping Cart 0
countryflagNZ
Login

Arcus Biosciences Inc

Healthcare US RCUS

31.0USD
0.75(2.48%)

Last update at 2026-06-26T20:04:00Z

Day Range

29.3031.03
LowHigh

52 Week Range

6.5018.98
LowHigh

Fundamentals

  • Previous Close 30.25
  • Market Cap906.38M
  • Volume4321689
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-426.00000M
  • Revenue TTM141.00M
  • Revenue Per Share TTM1.51
  • Gross Profit TTM -320.00000M
  • Diluted EPS TTM-4.23

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -266.00000M 54.65M -122.85800M -84.71000M -49.59400M
Minority interest - - - - -
Net income -267.00000M 52.83M -116.67700M -75.93100M -49.59400M
Selling general administrative 104.00M 72.29M 42.40M 25.23M 13.57M
Selling and marketing expenses - - - - -
Gross profit 112.00M 382.88M 77.52M 15.00M 8.35M
Reconciled depreciation 6.00M 3.84M 4.19M 3.58M 3.66M
Ebit -280.00000M 54.25M -124.23500M -92.28700M -59.75200M
Ebitda -264.00000M 54.91M -124.84800M -88.70900M -56.08800M
Depreciation and amortization 16.00M 0.66M -0.61300M 3.58M 3.66M
Non operating income net other - 0.40M 1.38M 4.00M 5.26M
Operating income -280.00000M 54.25M -124.23500M -88.70900M -54.85900M
Other operating expenses 392.00M 328.63M 201.75M 103.71M 63.21M
Interest expense 2.00M 0.26M 0.00000M 0.00000M 4.92M
Tax provision 1.00M 1.81M - - -
Interest income 16.00M 0.66M 1.38M 5.20M 4.92M
Net interest income 14.00M 0.40M 1.38M 5.20M 4.92M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 1.00M 1.81M -6.18100M -8.77900M 5.26M
Total revenue 112.00M 382.88M 77.52M 15.00M 8.35M
Total operating expenses 392.00M 328.63M 201.75M 103.71M 63.21M
Cost of revenue - - - - 49.65M
Total other income expense net 14.00M 0.40M 1.38M 4.00M 0.34M
Discontinued operations - - - - -
Net income from continuing ops -267.00000M 52.83M -122.85800M -84.71000M -49.59400M
Net income applicable to common shares -267.00000M 52.83M -122.85800M -84.71000M -49.59400M
Preferred stock and other adjustments - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 1150.00M 1095.00M 1345.00M 1591.90M 772.29M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 13.00M 30.00M 58.00M 15.62M 5.47M
Total liab 665.00M 633.00M 688.00M 750.45M 269.99M
Total stockholder equity 485.00M 462.00M 657.00M 841.45M 502.30M
Deferred long term liab - - 3.00M 4.00M 3.20M
Other current liab 122.00M 65.00M 76.00M 0.05M 3.57M
Common stock 1617.00M 1311.00M 1206.00M 0.00700M 0.00600M
Capital stock 1617.00M 1311.00M 1206.00M 0.00700M 0.00600M
Retained earnings -1132.00000M -849.00000M -542.00000M -275.35400M -328.18400M
Other liab - - 378.00M 467.48M 133.08M
Good will - - - - -
Other assets - - 14.00M 10.73M 25.67M
Cash 150.00M 127.00M 206.00M 147.91M 173.41M
Cash and equivalents - - - - -
Total current liabilities 226.00M 184.00M 193.00M 166.08M 121.67M
Current deferred revenue 85.00M 91.00M 97.00M 102.00M 74.57M
Net debt -90.00000M -116.00000M -206.00000M -31.02700M -158.17200M
Short term debt 12.00M 11.00M - 53.77M 27.85M
Short long term debt - - - - -
Short long term debt total 60.00M 11.00M - 116.89M 15.24M
Other stockholder equity - - -7.00000M 1118.06M 830.44M
Property plant equipment - - 135.00M 32.45M 10.81M
Total current assets 1016.00M 831.00M 1067.00M 681.30M 735.09M
Long term investments 14.00M 107.00M 129.00M 181.99M 6.44M
Net tangible assets - - 657.00M 841.45M 502.30M
Short term investments 828.00M 632.00M 803.00M 351.39M 555.23M
Net receivables 25.00M 42.00M 43.00M 746.82M 1.70M
Long term debt 48.00M - - - -
Inventory - - -172.00000M -762.44200M -7.16900M
Accounts payable 18.00M 17.00M 20.00M 10.26M 15.68M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - -7.00000M -1.26100M 0.04M
Additional paid in capital - - - - -
Common stock total equity - - - 0.00700M 0.00600M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -275.35400M -328.18400M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 73.00M 106.00M 114.00M 591.19M 7.18M
Deferred long term asset charges - - - - -
Non current assets total 134.00M 264.00M 278.00M 910.60M 37.21M
Capital lease obligations 12.00M 11.00M - 116.89M 15.24M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -413.00000M -28.79100M -431.31200M 61.14M -109.69700M
Change to liabilities -104.00000M 4.87M 24.07M 3.28M 3.12M
Total cashflows from investing activities -413.00000M -3.86800M -434.36700M 59.21M -113.44000M
Net borrowings - - - - -
Total cash from financing activities 33.00M 237.34M 438.68M 1.12M 129.07M
Change to operating activities 23.00M 14.09M 21.32M 0.53M 1.75M
Net income -267.00000M 52.83M -122.85800M -84.71000M -49.59400M
Change in cash 58.00M -22.69900M 115.48M -13.12700M -27.36200M
Begin period cash flow 151.00M 173.62M 58.14M 71.27M 98.43M
End period cash flow 209.00M 150.92M 173.62M 58.14M 71.06M
Total cash from operating activities 438.00M -256.17100M 111.17M -73.46200M -42.99600M
Issuance of capital stock 23.00M 220.24M 433.78M 1.22M 125.11M
Depreciation 6.00M 3.84M 4.19M 3.58M 3.66M
Other cashflows from investing activities 3.00M 51.00M 3.00M 61.14M -109.69700M
Dividends paid - - - - -
Change to inventory - 14.09M 21.32M 1.07M -
Change to account receivables 704.00M -17.04600M -0.91700M -0.13200M -0.13200M
Sale purchase of stock - -0.00600M -0.05400M 1.12M 124.98M
Other cashflows from financing activities 10.00M 17.11M 4.95M -0.09400M 3.96M
Change to netincome 76.00M 54.53M 21.82M 10.18M 3.35M
Capital expenditures 12.00M 26.08M 3.06M 1.93M 3.74M
Change receivables - - - 0.08M -0.05800M
Cash flows other operating - -377.01100M 185.03M -3.24000M -1.72800M
Exchange rate changes - - - - -
Cash and cash equivalents changes - -22.69900M 115.48M -13.12700M -27.36200M
Change in working capital 623.00M -375.61800M 208.06M 0.12M 1.33M
Stock based compensation 65.00M 54.53M 21.82M 8.98M 3.87M
Other non cash items 11.00M 3.47M -0.04600M -1.43600M -0.17700M
Free cash flow 426.00M -282.24900M 108.11M -75.38700M -46.73900M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
RCUS
Arcus Biosciences Inc		 0.75 2.48% 31.00 - - 6.43 1.71 2.34 3.96
NVO
Novo Nordisk A/S		 0.43 0.90% 48.07 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 47.84 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 11.16 2.32% 491.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 12.76 2.06% 632.90 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; and Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer; Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in phase 2 clinical trial for colorectal cancer; and Zimberelimab, an anti-PD-1 antibody. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer; and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Arcus Biosciences Inc

3928 Point Eden Way, Hayward, CA, United States, 94545

Key Executives

Name Title Year Born
Dr. Terry J. Rosen Ph.D. Co-Founder, Chairman & CEO 1960
Dr. Juan Carlos Jaen Ph.D. Co-Founder, Pres & Director 1958
Mr. Robert C. Goeltz II Principal Financial & Accounting Officer and CFO 1973
Ms. Jennifer A. Jarrett M.B.A. COO & Director 1971
Ms. Carolyn C. Tang J.D. Gen. Counsel & Corp. Sec. 1979
Dr. K. Christopher Garcia Ph.D. Co-Founder & Member of Scientific Advisory Board NA
Dr. Stephen Young Ph.D. Sr. VP of Technology & Quantitative Biology 1969
Dr. Jonathan Yingling Ph.D. Chief Scientific Officer 1969
Ms. Katherine Bock VP of Investor Relations & Corp. Strategy NA
Holli Kolkey VP of Corp. Communications NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.